STAAR Surgical Company
STAAR Surgical Company (STAA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
staa · pe ratio · data through Jan 2, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for STAAR Surgical Company (STAA) measures how much investors pay for each dollar of the company's trailing earnings. STAA's current PE ratio of N/A is calculated by dividing its stock price of $30.19 by its TTM earnings per share of -$0.42.
Source: FMP · /ratios-ttm · /analyst-estimates · 2026-01-02
PE Ratio History
2006 – 2026 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 9 fiscal years · Front-end computedMinQ1 · 25%275.7x
MedianQ3 · 75%4008.2x
Max
At N/A, STAA's current P/E is lower than in 0% of its annual fiscal year readings over the past 9 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Instruments & Supplies · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
STAAR Surgical CompanyYou STAA | $1.5B | N/A | — | -$0.42 |
 Azenta, Inc. AZTA | $1.0B | N/A | — | -$1.22 |
 Beta Bionics, Inc. BBNX | $619M | N/A | — | -$1.81 |
 BioLife Solutions, Inc. BLFS | $1.3B | N/A | — | -$0.25 |
 Kestra Medical Technologies, Ltd. KMTS | $1.2B | N/A | — | -$2.30 |
 NovoCure Limited NVCR | $2.0B | N/A | — | -$1.22 |
 ORIC Pharmaceuticals, Inc. ORIC | $779M | N/A | — | -$1.47 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2026-01-02Latest FY2026 | — | $-1.62 | — | |
2024-12-27 FY2024 | — | $-0.41 | — | |
2023-12-29 FY2023 | 70.94x | $0.44 | +20.8% | |
2022-12-30 FY2022 | 58.72x | $0.83 | -62.5% | |
2021-12-31 FY2021 | 156.67x | $0.58 | -74.4% | |
2021-01-01 FY2021 | 611.00x | $0.13 | +461.1% | |
2020-01-03 FY2020 | 108.89x | $0.32 | -61.7% | |
2018-12-28 FY2018 | 284.18x | $0.11 | — | |
2017-12-29 FY2017 | — | $-0.05 | — | |
2016-12-30 FY2016 | — | $-0.30 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for STAAR Surgical Company (STAA) measures how much investors pay for each dollar of the company's trailing earnings. STAA's current PE ratio of N/A is calculated by dividing its stock price of $30.19 by its TTM earnings per share of -$0.42.
Frequently asked questions
STAA pe ratio · 6 questionsSTAA's current PE ratio is N/A as of 2026-06-08, based on a stock price of $30.19 and TTM EPS of -$0.42. Data sourced from Financial Modeling Prep via STAA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · STAAR Surgical Company SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08